Eric Van Cutsem, MD, PhD

Eric Van Cutsem, MD, PhD, University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses regorafenib for the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC). He and his colleagues conducted the nonrandomized, phase IIIb CONSIGN study, in order to examine the effects of regorafenib in these previously treated patients.

After seeing the CORRECT study, which showed that regorafenib improves survival, the goal of the CONSIGN study was to include a larger number of patients, said Van Cutsem. The primary endpoint was to look at the safety of regorafenib and learn more about how to improve tolerance of the drug.

Videos

Eric Van Cutsem, MD, PhD, discusses regorafenib for the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC). 

Dr. Van Cutsem Discusses Regorafenib for the Treatment of Patients With Chemorefractory mCRC

Eric Van Cutsem, MD, PhD, at University Hospitals Gasthuisberg/Leuven in Leuven, Belgium, discusses the challenges of using chemotherapy to treat patients with gastric cancer.

Using trastuzumab or other anti-HER2 agents when treating patients with gastric cancer does not eliminate the need to use chemotherapy.

Patients with gastric cancer are often in poor health to begin with and have low tolerance levels and fast occurrances of resistance after undergoing chemotherapy.

There is room for growth and improvement in chemotherapy in order to determine if the treatments can contain less toxicities, which remains a challenge for patients in regards to their overall means of survival.

Articles

Eric Van Cutsem, MD, PhD, discusses the challenges of using chemotherapy to treat patients with gastric cancer.

Eric Van Cutsem, MD, PhD | Authors

Articles

Dr. Van Cutsem Discusses Regorafenib for the Treatment of Patients With Chemorefractory mCRC

Chemotherapy Treatment in Gastric Cancer